Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969336 | 0.87 | PLK1 (0.81) | PLK1TSHRSMN1; SMN2GAAMMP1 | |
| SCHEMBL12839873 | 0.86 | PLK1 (0.87) | PLK1TSHRHPGDHTTSMN1; SMN2 | |
| SCHEMBL14969349 | 0.85 | PLK1 (0.79) | PLK1TSHRTP53 | |
| SCHEMBL12112441 | 0.85 | PLK1 (0.79) | PLK1TSHRTP53 | |
| SCHEMBL12113898 | 0.85 | PLK1 (0.79) | PLK1TSHRTP53 | |
| SCHEMBL18914860 | 0.85 | PLK1 (0.73) | PLK1TSHRHPGDHTTSMN1; SMN2 | |
| SCHEMBL4751615 | 0.83 | PLK1 (0.75) | PLK1TSHRHPGDHTTSMN1; SMN2 | |
| SCHEMBL4751488 | 0.83 | PLK1 (0.75) | PLK1TSHRHPGDHTTSMN1; SMN2 | |
| SCHEMBL11962158 | 0.83 | PLK1 (1.00) | PLK1TSHRHPGDHTTSMN1; SMN2 | |
| SCHEMBL23484979 | 0.83 | PLK1 (0.74) | PLK1TSHRSMN1; SMN2MMP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1541574-A1 | TRIAZASPIRO 5.5 UNDECANE DERIVATIVES AND DRUGS COMPRISI NG THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | HLA-DRB1, TLR5, HLA-C | PLK1 2286/4885TSHR 2682/4885HPGD 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.